Skip to main content

Table 3 Least-squares mean percentage breast density by menopausal and HRT status

From: Genetic determinants of mammographic density

   Postmenopausal/HRT status*  
Genotype Premenopausal* mean (n) Never and past use mean (n) Current use** mean (n) P ***
CYP17     
   A1/A1 34.0 (58) 31.9 (26) 37.9 (39)  
   A1/A2 35.7 (94) 30.5 (33) 38.6 (52)  
   A2/A2 37.9 (24) 24.9 (8) 48.6 (13)  
P trend 0.39 0.42 0.16 0.13
COMT     
   Val/Val 36.9 (62) 29.7 (20) 33.7 (39)  
   Val/Met 34.4 (70) 31.6 (40) 42.3 (46)  
   Met/Met 34.9 (44) 25.3 (7) 45.4 (19)  
P trend 0.56 0.80 0.01 0.10
17HSDB1     
   Gly/Gly 32.0 (52) 24.0 (13) 41.1 (32)  
   Gly/Ser 35.5 (76) 33.7 (40) 39.4 (47)  
   Ser/Ser 39.1 (48) 26.9 (14) 38.2 (25)  
P trend 0.07 0.77 0.57 0.65
3HSDB1     
   Asn/Asn 35.5 (106) 32.8 (42) 40.6 (61)  
   Asn/Thr 33.4 (56) 25.8 (23) 40.8 (32)  
   Thr/Thr 42.7 (14) 31.8 (2) 28.9 (9)  
P trend 0.55 0.27 0.22 0.95
  1. *Adjusted for race, age, body mass index, parity, age at first birth, age at menarche and first-degree family history of breast cancer. **Current use of estrogen replacement therapy or estrogen plus progestin replacement therapy. *** P value for interaction between hormone replacement therapy (HRT) status (never used and past use versus current use) and genotype (ordinal).